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Abstract: Osteoarthritis is one of the most common causes of lameness and often is a career-ending disease
in horses. Treatment of osteoarthritis is usually symptomatic and aimed at controlling the inflamma-
tion, either systemically or intra-articularly. Common intra-articular treatments include corticosteroids
combined with hyaluronic acid and chondroprotective drugs such as glucosamine and chondroitin. The
application of gold compounds, either orally or intramuscularly, has been used therapeutically for many
decades, primarily in human patients with rheumatoid arthritis. Gold compounds (aurothiomalate) in-
hibit the production of nitric oxide (NO) of chondrocytes. Nitric oxide mediates the destructive effects of
IL-1 and TNF, which include reduced collagen and proteoglycan production, apoptosis of chondrocytes
and stimulation of metalloproteases. The purpose of the present study was to compare the efficacy of the
GOLDIC® treatment with that of corticosteroids and hyaluronic acid in horses with arthrogenic lameness.
A prospective randomized controlled, two-centre clinical trial was performed. 30 horses with arthrogenic
lameness were enrolled in this study. The horses were treated by four injections of gold-induced, au-
tologous conditioned serum GOLDIC® (group B, n = 16) or by a single injection of corticosteroid and
hyaluronic acid (group A, n = 14). Lameness was assessed using the AAEP Grading system before and
3, 6, 12 and 36 months after treatment. The AAEP grade was the primary endpoint. Differences were
considered significant at P < 0.05. Secondary endpoints were the results of the flexion test, degree of
joint-effusion, radiographic findings, the ability to return to original performance level and adverse effects.
Horses of group B had significantly lower lameness grades at the follow-up examinations compared with
the value before treatment (p < 0.01). Both treatment groups showed positive effects on the AAEP-
Score. Group B (Goldic®) showed much faster effect on the AAEP-Score. Also in the long run group B
(Goldic®) showed a larger effect on the AAEP-Score. Severe side effects did not occur in either group.
It has been shown that the treatment of arthrogenic lameness in horses with the gold-induced, autolo-
gous conditioned serum method (GOLDIC®) is in certain cases a promising alternative to conventional
treatment with corticosteroids and hyaluronic acid.
DOI: https://doi.org/10.21836/pem20200301
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Summary: Osteoarthritis is one of the most common causes of lameness and often is a career-ending disease in horses. Treatment of osteo-
arthritis is usually symptomatic and aimed at controlling the inflammation, either systemically or intra-articularly. Common intra-articular treat-
ments include corticosteroids combined with hyaluronic acid and chondroprotective drugs such as glucosamine and chondroitin. The appli-
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rum GOLDIC® (group B, n = 16) or by a single injection of corticosteroid and hyaluronic acid (group A, n = 14). Lameness was assessed using 
the AAEP Grading system before and 3, 6, 12 and 36 months after treatment. The AAEP grade was the primary endpoint. Differences were 
considered significant at P < 0.05. Secondary endpoints were the results of the flexion test, degree of joint-effusion, radiographic findings, the 
ability to return to original performance level and adverse effects. Horses of group B had significantly lower lameness grades at the follow-up 
examinations compared with the value before treatment (p < 0.01). Both treatment groups showed positive effects on the AAEP-Score. Group 
B (Goldic®) showed much faster effect on the AAEP-Score. Also in the long run group B (Goldic®) showed a larger effect on the AAEP-Score. 
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Introduction
Degenerative joint disease is very common in humans and in 
horses (Rossdale et al. 1985, Lawrence et al. 1998, Johnston 
1997). In humans, osteoarthritis frequently occurs in elderly 
patients, but also in young people as a post-traumatic com-
plication (Buckwalter 2003, Buckwalter and Brown 2004). 
The latter is also a problem in horses because osteoarthritis 
effects primarily sports horses (McIlwraith 1996). Joint pain 
impairs normal joint function and severely restricts the quality 
of life in human and equine patients (Lawrence et al. 1998). 
Osteoarthritis is one of the most common causes of lameness 
and often is a career-ending disease in horses (Rossdale et 
al. 1985), even more so than fatal fractures (Cruz and Hur-
tig 2008, Pool and Meagher 1990). Abnormal weight-bear-
ing, joint instability and joint infection lead to mechanical 
and enzymatic damage to the joint cartilage with apoptosis 
of chondrocytes and loss of type II collagen and proteogly-
cans (McIlwraith 1996, Luko schek et al. 1986, Simmons et 
al. 1999, Norrdin et al. 1998, Green et al. 2006, Guilak et 
al. 2004, Buckwalter 1995). Although the main component 
of the pathogenesis of osteoarthritis is the degeneration of the 
joint cartilage, the joint capsule and the subchondral bone 
are also affected (McIlwraith 1996, Cruz and Hurtig 2008, 
Young et al. 2007). The subchondral bone becomes denser 
than normal and sclerotic because of large cyclic loads that 
lead to impaired shock absorption. In addition, shear forces 
occur at the interface between the subchondral bone plate 
and mineralised cartilage (McIlwraith 1996, Cruz and Hurtig 
2008, Radin and Rose 1986). 
The synovial fluid of horses with chronic joint disease has 
higher levels of tumour necrosis factor (TNF), interleukin 1 
(IL-1), IL-6 and prostaglandin E2 (PGE2) than normal horses 
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(Bertone et al. 2001). The same pro-inflammatory cytokines 
are also elevated in people with osteoarthritis (Kobayashi et 
al. 2005). Inflammatory cells of the synovial membrane, sy-
noviocytes and chondrocytes secrete cytokines (Spiers et al. 
1994, Clegg et al. 1997a, Clegg et al. 1997b, David et al. 
2007, Samuels et al. 2008, Goldring et al. 1988, Loeser 
2006, Bondeson et al. 2006) and stimulate the release of 
metalloproteinase (MMO's) and aggrecanasis (Bondeson et 
al. 2006), as well as other inflammatory mediators like pros-
taglandins (PGE2) or nitric oxide (NO) (Guilak et al. 2004, 
Pelletier et al. 2001, von Rechenberg et al. 2000). 
Treatment of osteoarthritis is usually symptomatic and aimed 
at controlling the inflammation, either systemically or intra-ar-
ticularly (Caron 2005, Fortier 2005). Common intra-articular 
treatments include corticosteroids combined with hyaluronic 
acid (Frean et al. 2002, Schaefer et al. 2009, Trotter 1996) and 
chondroprotective drugs such as glucosamine and chondroitin 
(Frean et al. 2002, Frisbie et al. 2009). Intra-articular injection 
of cytokine inhibitors, which include interleukin 1 receptor an-
tagonists (IL-1Ra) have been used successfully in horses with 
osteoarthritis (Frisbie et al. 2007) and in humans with osteo-
arthritis and rheumatoid arthritis (Baltzer et al. 2003, Baltzer 
et al. 2009, Bresnihan et al. 1998). Orthokine/IRAP therapy 
involves the intra-articular injection of autologous conditioned 
serum in which the natural components that block interleukin-1 
have been amplified. Incubation of autologous venous blood 
with chrome sulphate-impregnated glass pearls was shown to 
amplify the production of anti-inflammatory mediators (Meijer 
et al. 2003). However, the study by Warner et al. questions the 
long-term therapeutic success of this treatment (Warner et al. 
2016). Another treatment approach is the intraarticular appli-
cation of Polyacrylamide hydrogel (PAAHG). With this therapy, 
promising results in the treatment of osteoarthritis of the distal 
interphalangeal joint could be achieved (Janssen et al. 2012).
The application of gold compounds, either orally or intramuscu-
larly, has been used therapeutically for many decades (Jaeger et 
al. 2006, Schneider 2011, Schneider and Veith 2013), primarily 
in human patients with rheumatoid arthritis. Currently, gold salts 
are administered subcutaneously in the form of gold sticks, and 
the newest form, termed extra-corporal inductive therapy, con-
sists of gold-induced autologous conditioned serum (GOLDIC®). 
Gold compounds (aurothiomalate) inhibit the production of nitric 
oxide (NO) of chondrocytes. Nitric oxide mediates the destruc-
tive effects of IL-1 and TNF (Green et al. 2006), which include 
reduced collagen and proteoglycan production, apoptosis of 
chondrocytes and stimulation of metalloproteases (Vuolteenaho 
et al. 2005). GOLDIC® in vitro studies showed that it not only 
inhibits catabolic factors, but increases anti-catabolic and ana-
bolic factors. Amongst other things, it could be proved that Gel-
solin, key-protein in cell-metabolism, is increased significantly 
(Schneider 2011). In a large uncontrolled case study that consti-
tuted the first report of the clinical application of the GOLDIC® 
technique, the treatment of horses with different grades of joint 
disease and lameness resulted in marked improvement in clini-
cal signs (Schneider and Veith 2013). However, the purpose of 
that study was merely to screen the usefulness of GOLDIC® for 
the treatment of arthrogenic lameness in horses. 
The purpose of the present study was to compare the efficacy 
of the GOLDIC® treatment with that of corticosteroids and 
hyaluronic acid in horses with osteoarthritis. The hypothesis 
was that both treatments have a therapeutic effect but that the 
effect of the GOLDIC® treatment is greater.
Material and methods
This clinical study was designed as a prospective randomized 
controlled lameness trial: The study included horses that were 
admitted to the Equine Clinic at the Vetsuisse Faculty of the Uni-
versity of Zurich and to the private equine clinic “Fohlenweide” 
(Heigenkam, Germany) because of lameness attributable to 
arthropathy. The criteria for inclusion into the study were as 
follows: the lameness had been present for a minimum of three 
weeks, the lameness was caused by joint disease diagnosed 
using nerve blocks and if possible imaging modalities and sys-
temic or intra-articular treatments had not been carried out in 
the previous three weeks. Horses with conditions amenable to 
surgical treatment (e.g. osteochondritis) were excluded. After 
history taking, the horses underwent clinical and orthopaedic 
examinations. Thirty horses fulfilled the criteria for inclusion into 
this study, 16 of which were treated with the GOLDIC® method 
and 14 with betamethasone and hyaluronic acid. The mean 
age was 12.2 years (range 4 to 18 years) in group A and 10.7 
years (2 to 18 years) in group B. The signalment of the horses, 
the history, the joint affected and adverse effects of treatment 
are shown in Table 1. Lameness was assessed using the AAEP 
Grading system (AAEP 2019). The results of the flexion test and 
the degree of joint effusion were classified as 0 (negative), 1 
(mild), 2 (moderate) and 3 (severe). At the end of treatment, the 
degree of improvement of lameness was assessed. 
The different groups were randomized on the basis of a com-
puter-generated list: Group A (Hyaluronic acid/steroid) and 
Group B (GOLDIC®). 
Group A: Horses in this group were given a single intra-articular 
injection of 12–18 mg betamethasone acetatea and 20 mg hy-
aluronic acidb. The injection site was prepared aseptically, and 
depending on the temperament of the horse, xylazinec (0.5 mg/
kg) and butorphanold (0.02 mg/kg) were given for sedation.
Group B: Horses in this group received 4 ml GOLDIC®e ac-
tivated serum once per week for four weeks using the same 
injection technique as in group A. The horses underwent clini-
cal examination before each injection, and the degree of joint 
effusion, swelling and other abnormalities were recorded.
Preparation of GOLDIC®
The gold-induced, autologous-conditioned serum was pro-
duced in accordance to the manufacturer's guidelines (Arthro-
gen GmbH). The first injection was performed on day 1 after 
serum incubation; the other three serum aliquots were stored 
at –20 °C until the designated day of injection. 
Aftercare
After each joint injection, the horses were confined to a box 



























































Table 1 Codes of the study horses, sex, age, diagnosis, localisation of the arthrogenic lameness, duration of lameness and clinical evaluations of the treated horses. Group A was treated with a single corti-
costeroid and hyaluronic acid injection, group B with GOLDIC® injections.    |    Codes der Versuchspferde, Geschlecht, Alter, Diagnose, Lokalisation der arthrogenen Lahmheit, Dauer der Lahmheit und klinische 
Bewertungen der behandelten Pferde. Gruppe A wurde mit einer einzigen Kortikosteroid- und Hyaluronsäure-Injektion behandelt, Gruppe B mit GOLDIC®-Injektionen.
Group Age (y) Sex Diagnosis Localisation Duration Joint Anesthesia Return to Function Adverse Events
A 3 f Sclerosis third carpal bone carpal joint front left weeks positive yes no
A 18 f hgr OA tarosmetatarsal joint right months positive   no
A 11 m lgr OA carpal and carpo-metacarpal joint left months positive no no
A 7 m no OA stifle joint weeks positive no no
A 10 m no Rx tarosmetatarsal joint weeks positive yes no
A 17 m mgr OA fetlock joint left forelimb weeks positive yes no
A 5 f no Rx fetlock joint left forelimb weeks positive yes no
A 2 m no Rx stifle joint weeks - yes no
A 16 f  lgr OA  pastern joint hind leg right weeks positive  ? joint flare after anesthesia
A 17 m lgr-mgr OA coffin joint both forlimbs months positive no no
A 3 f mgr OA carpal joint right forelimb weeks - yes no
A 16 f lgr OA fetlock joint right forelimb months - no no
A 18 m hgr OA talocalcanean joint weeks positive no no
A 8 f mgr OA antebrachiocarpal joint left weeks positive   joint flare after anesthesia
B 11 m cyst femoral condyle stifle joint months positive no no
B 18 f mgr OA fetlock joint left forelimb months - yes no
B 12 m mgr OA Scapulohumeral joint months - no no
B 17 f no OA coffin joint right forelimb months positive no increase of lameness for 24 h
B 4 f no Rx carpal joint left forelimb weeks positive yes
increased swelling after the first 
injection
B 8 f lgr OA coffin joints both forelimbs weeks positive yes no
B 5 f mgr -hgr OA carpal joint right forelimb weeks -   no
B 16 m mgr OA coffin joint left forelimb weeks positive yes no
B 17 m hgr OA coffin joint right forelimb weeks positive yes no
B 18 m mgr OA hock right side months positive yes no
B 6 m mgr OA MCG right months positive yes no
B 10 m mgr -hgr OA coffin joint left forelimb weeks positive yes no
B 18 m mgr OA carpal joint right forelimb months positive yes no
B 10 m mgr -hgr OA coffin joint both forelimbs months positive yes no
B 13 m mgr OA coffin joint right side months positive yes no
B 13 f mgr -hgr OA coffin joint right side months positive yes
increased swelling after the 
second injection
(hgr OA = high grade osteoarthritis; mgr OA = mid grade osteoarthritis, lgr OA = low grade osteoarthritis; Rx = x-ray)     |    (hgr OA = hochgradige Osteoarthritis; mgr OA = mittelgradige Osteoarthritis; lgr OA = leichtgradige Osteoarthritis; 
x = Röntgenaufnahme)
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the entire duration of the treatment. At the end of the treat-
ment period, exercise was gradually increased depending on 
the degree of lameness.
Outcome
The main endpoint was the degree of lameness assessed us-
ing the AAEP Grading system 3, 6, 12 and 36 months after 
treatment. Further endpoints were the recovery to the point of 
full function of the leg, and radiographic findings (osteoar-
throsis progression). 
Power analysis
The number of patients required to detect an effect of the 
GOLDIC® method was determined based on a previous pilot 
study (Schneider and Veith 2013). The AAEP lameness grade 
was the primary endpoint and a decrease in lameness by one 
grade was considered clinically significant. A sample size of 
28 patients was required for 80 % power (α = 0.05, standard 
deviation = 1.3) to reject the null hypothesis that both treat-
ments were equal. Therefore, 30 horses were used in the 
present study. 
Statistical analysis
The program Sigma Stat 3.5 was used for statistical calcu-
lations. To determine how closely the data fits a normal dis-
tribution, we computed a Kolmogorov-Smirnov Goodness 
of Fit test. The data could not be assumed to be reasonably 
normally distributed. For further analyzes we used non-para-
metric statistical tests. For tests within each group (HA+S and 
GOLDIC®) we used Friedman‘s Two Way ANOVA of Ranks 
and Wilcoxon signed Rank Test. For tests between the groups 
(HA+S and GOLDIC®) we used Mann-Whitney U Test. As 
Mann-Whitney U Tests between T0 values of both groups 
(HA+S and GOLDIC®) showed that the two samples are not 
distributed identically, it was not usefull to compare the T1, 
T2, T3, T4 values directly between the two groups (HA+S and 
GOLDIC®). We defined DELTA values for T1-T4 as the differ-
ence relative to T0 using Mann-Whitney U Test.
Results
All horses showed a marked improvement in their degree of 
lameness by time. The AAEP scores of all horses are demon-
strated in Figure 1. 
Both treatment groups have a positive temporal development 
of the AAEP-Score. Comparison of the different times within 
each group shows higher differences with lower probabilities 
for same distribution in group B (GOLDIC®). Also, the DELTA 
Values are higher in group B (GOLDIC®).
In Figure 1, AAEP-Score Means showed clearly that in group A 
(HA+S) we have a nearly linear temporal development of the 
AAEP-Score over all Times T0-T4. In group B (GOLDIC®) we 
found a much stronger but also nearly linear improvement of 
the AAEP-Score over T0-T2. Looking at T0-T4 it seems that we 
have an asymptotic approach to a minimum value after T2.
In the GOLDIC® group 13 of 16 horses got back to their orig-
inal performance level while three horses were competing at a 
lower level than before. In this group, we had 2 drop outs at 
12 months. One horse could not be followed after being sold 
to a new owner. The other horse was euthanized based on the 
cyst in the treated joint.
On the other side, the control group had 6 horses out of 14, 
which went back to their original state of performance while 
five weren’t capable of getting back. We had one lost of fol-
low-up after 3 and 6 months based on another disease and 2 
further drop-outs after 3 years (the owner of these two horses 
could not be reached for documentation). 
The GOLDIC® group had two horses with radiological pro-
gression, but they were still capable of being used in their full 
and original activity. In both groups, no severe side effects 
could be seen. Nevertheless, one horse got worse for about 
one grade for a few days while treatment was done.
The age, sex, radiological morphology and duration of lame-
ness had no effect on the results of treatment.
Discussion
This is the first study of the efficacy of the injections of gold-in-
duced, autologous conditioned serum (GOLDIC®) for the 
treatment of arthrogenic lameness in horses in a prospective 
comparative study. Intra-articular injections of a corticosteroid 
and hyaluronic acid, which is commonly used and well estab-
lished in veterinary medicine, was used in the control group. 
Corticosteroids have been used for decades for this purpose 
and are considered a standard treatment for arthrogenic 
lameness in veterinary medicine (Frean et al. 2002, Schaefer 
et al. 2009, Trotter 1996). However, treatment with cortico-
steroids is strictly symptomatic because it does not affect the 
aetiology of the disease process. A major drawback is the 
introduction of crystalline steroidal elements into the joint. Re-
peated intra-articular injections of corticosteroids can cause 
irritation of the intra-articular structures because of aggrega-
Fig. 1 AAEP lameness scores of all horses in groups A (blue line) 
and B (red line) before treatment and at follow-up examinations.    |
AAEP-Lahmheitsbewertungen aller Pferde in den Gruppen A (blaue 
Säulen) und B (rote Säulen) vor der Behandlung und bei Folgeunter-
suchungen. 
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tion of these crystals (Jones and Doherty 1996, Friedman and 
Moore 1980, Gaffney et al. 1995). 
The treatment of arthrosis with hyaluronic acid is controversial 
in human medicine (Caborn et al. 2004, Day et al. 2004, Lee 
et al. 2006, Lundsgaard et al. 2008, Raman et al. 2008, Ray-
nauld et al. 2003, Huang et al. 2011, Juni et al. 2007, Puhl 
et al. 1993, Qvist et al. 2008, Maheu et al. 2011). Although 
many studies have investigated this drug a positive effect on 
damaged joint cartilage has not been demonstrated (Rutjes 
et al. 2012). Recently, the American Academy of Orthopedic 
Surgeons published a retraction of a recommendation for the 
treatment of knee osteoarthritis with hyaluronic acid products 
based on a meta-analysis (Jevsevar et al. 2013) but hyaluron-
ic acid continues to be used by physicians.
Several novel treatments based on biological processes rather 
than providing mere pain control have recently been intro-
duced, but the demonstration of efficacy has been difficult 
(Broeckx et al. 2019). The use of the interleukin-1 receptor 
antagonist protein (IRAP®), cell-based procedures such as 
platelet-rich plasma (PRP) and the transplantation of mesen-
chymal stem-cells have not proven useful for the treatment 
of degenerative joint disease in horses (Bertone et al. 2014, 
Ehrle et al. 2013, Fahie et al. 2013, Franklin and Cook 
2013). In the daily use, they are often viewed critically (Hild-
ner et al. 2011). 
We designed a prospective and controlled study to investigate 
the effect of the GOLDIC® method for the treatment of arthro-
genic lameness in horses with the final follow-up examination 
at 3 years. This was done to critically examine long-term ef-
fects of the treatments. The follow-up period was longer than 
in other studies that investigated the treatment of arthrogenic 
lameness. 
Both treatments tested in this study led to a decrease in lame-
ness but the effect of the GOLDIC® technique was greater 
and statistically significant. Only the horses treated with the 
GOLDIC® method had significantly lower lameness grades 3 
years after treatment than before treatment. The results of the 
present study are in agreement with another study that also 
documented significant long-lasting benefits of the GOLDIC® 
method in the treatment of arthrogenic lameness in horses 
(Schneider 2011, Schneider et al. 2017).
The mode of action of the GOLDIC® procedure is not well 
understood. Nevertheless, GOLDIC® has shown in in-vitro 
studies that plasma Gelsolin could be elevated in the auto-
logous serum significantly (Schneider et al. 2017). Gelsolin 
is an actin-binding protein and occurs in cells (cytoskele-
ton) and in plasma (Silacci et al. 2004). The cytoskeleton 
is responsible for the viscoelasticity of this cells (Trickey et 
al. 2004). Furthermore, important functions of cells are reg-
ulated by Gelsolin: Cell motility, phagocytosis, apoptosis 
and the activation of thrombocytes (Silacci et al. 2004). The 
concentration of Gelsolin in plasma is decreased accord-
ing to different tissue degenerating diseases (Suhler et al. 
1997). Experiments have shown decreased plasma Gelsolin 
concentrations in animals with sepsis, and treatment with 
Gelsolin had a positive effect on the survival rate in these 
animals (Lee et al. 2007). Plasma Gelsolin serves as a buf-
fer to intercept inflammatory reactions of the body (DiNubile 
2008) and was found to be decreased in rheumatic arthritis 
(Osborn et al. 2008). 
It was beyond the scope of this study to collect serum and 
synovial fluid samples for measurements of Gelsolin in re-
sponse to the GOLDIC® treatment. A clinical study of hu-
man osteoarthritis in knee joints showed that intra-articular 
Table 2 AAEP lameness in groups A and B before treatment and 
at follow-up examinations (Median values including 25th and 75th 
percentiles and lost of follow-up    |    AAEP-Lahmheit in den Gruppen 
A und B vor der Behandlung und bei Nachuntersuchungen (Median-
werte einschließlich 25. und 75. Perzentil und Verluste bei Nachunter-
suchungen
Group N Missing  Median 25 % 75 %
Goldic pre 16 0 2’000 2’000 3’000
HA+S pre 14 0 3’000 3’000 3’000
Goldic 3mo 16 0 2’000 1’000 2’000
HA+S 3mo 13 1 3’000 2’250 3’000
Goldic 6mo 16 0 1’000 0.000 1’000
HA+S 6mo 13 1 2’000 2’000 3’000
Goldic 12 mo 16 2 0.500 0.000 1’000
HA+S 12mo 13 2 2’000 2’000 2’000
Goldic 3y 16 2 1’000 0.000 1’000
HA+S 3y 12 4 2’000 1’000 2’000
 HA+S = Hyaluronic acid and steroids)/ HA+S = Hyaluronsäure und Steroide
Table 3  Statistical analysis of the AAEP lameness grades score at 
different follow-up examinations demonstrated by differences of ranks, 
Q values and P values.    |    Die statistische Analyse der AAEP-Lahm-
heitsgrade ergab bei den verschiedenen Folgeuntersuchungen Unter-




Q P P < 0.050
Goldic pre vs Goldic > 3 y 62’955 4’464 <0.001 Yes
Goldic pre vs Goldic > 6 mo 62’277 4’416 <0.001 Yes
Goldic pre vs Goldic 3–6 56’531 4’149 0.002 Yes
HA+S < 3mo vs Goldic > 3 y 76’268 5’031 <0.001 Yes
HA+S < 3mo vs Goldic > 6 mo 75’589 4’986 <0.001 Yes
HA+S < 3mo vs Goldic 3–6 69’844 4’746 <0.001 Yes
HA+S 3–6 vs Goldic > 3 y 63’101 4’162 0.001 Yes
HA+S 3–6 vs Goldic > 6 mo 62’423 4’117 0.002 Yes
HA+S 3–6 vs Goldic 3–6 56’677 3’851 0.005 Yes
HA+S pre vs Goldic < 3mo 48’214 3’419 0.028 Yes
HA+S pre vs Goldic > 3 y 81’857 5’620 <0.001 Yes
HA+S pre vs Goldic > 6 mo 81’179 5’573 <0.001 Yes
HA+S pre vs Goldic 3–6 75’433 5’349 <0.001 Yes
HA+S < 3mo vs Goldic < 3mo 42’625 2’896 0.170 No
HA+S > 6 vs Goldic > 3 y 50’597 3’259 0.050 No
HA+S pre vs HA+S > 3 y 43’589 2’552 0.482 No
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treatment with gold-activated serum (GOLDIC®) resulted in 
a significant increase of Gelsolin in synovial fluid (Schneider 
2011).
One limitation of this study was the low number of cases and 
the heterogeneity of joints affected. Still, in this study, the in-
tra-articular treatment of arthrogenic lameness in horses with 
the GOLDIC® method yielded significantly better short- and 
long-term results than the traditional treatment with cortico-
steroids and hyaluronic acid. Further studies are needed to 
substantiate whether the beneficial effect of the GOLDIC® 
method is attributable to an increase in the actin-binding pro-
tein, Gelsolin, in synovial fluid. 
Manufacturer’s addresses 
a Celestone-Chronodose®, Essex Chemie, Switzerland
b SynovaMed AG, Liechtenstein
c Xylazin® Streuli Pharma Switzerland
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e Arthrogen med vet GmbH, Germany
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